Skip Navigation


Brain Advance Access originally published online on March 17, 2005
Brain 2005 128(5):1003-1015; doi:10.1093/brain/awh479
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
128/5/1003    most recent
awh479v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Omari, K. M.
Right arrow Articles by Raine, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Omari, K. M.
Right arrow Articles by Raine, C. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2005). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis

Kakuri M. Omari1, Gareth R. John4, Stuart C. Sealfon5 and Cedric S. Raine1,2,3

Departments of 1 Pathology (Neuropathology), 2 Neurology and 3 Neuroscience, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, 4 Corinne Goldsmith Dickinson Center for Multiple Sclerosis and 5 Department of Neurology, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY, USA

Correspondence to: Dr Kakuri M. Omari, Department of Pathology (Neuropathology), Albert Einstein College of Medicine, 1300 Morris Park Avenue, F-140, Bronx, NY 10461, USA E-mail: komari{at}aecom.yu.edu

Subsequent to demyelination in multiple sclerosis, myelin repair occurs but, as lesions age, the ability to remyelinate diminishes. Molecular pathways underlying oligodendrocyte behaviour during CNS remyelination remain to be elucidated. In this study, we report for the first time constitutive expression of the CXC/{alpha} chemokine receptors, CXCR1, CXCR2 and CXCR3, on oligodendrocytes in normal adult human CNS tissue, the levels of which were upregulated in multiple sclerosis and other neurological diseases (OND). In addition, both immature (A2B5+/O4+) and more mature (CNPase+) human oligodendrocytes in vitro expressed the same three receptors. The respective ligands to CXCR1, CXCR2 and CXCR3 [i.e. CXCL8/IL-8, CXCL1/GRO-{alpha} and CXCL10/IP-10), were absent in CNS tissue from normals and subjects with OND, but were present at high levels on hypertrophic (reactive) astrocytes at the edge of active (but not silent) multiple sclerosis lesions. Astrocytes in vitro could be induced to express chemokines following stimulation with pro-inflammatory cytokines. CXCL8 and CXCL1 production by human astrocytes at both the RNA and protein levels could be induced by interleukin (IL)-1ß, while CXCL10 was induced by both IL-1ß and interferon-{gamma}. Since these cytokines are integral to inflammatory events occurring at the margins of active multiple sclerosis lesions, their upregulation in these regions may underlie the dynamics of chemokine expression observed herein. The simultaneous expression of different CXC chemokine receptors on oligodendrocytes, and their ligands on astrocytes around multiple sclerosis lesions, may bespeak novel functional roles for these immune system molecules in the recruitment of oligodendrocytes and remyelination.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
K. M. Omari, S. E. Lutz, L. Santambrogio, S. A. Lira, and C. S. Raine
Neuroprotection and Remyelination after Autoimmune Demyelination in Mice that Inducibly Overexpress CXCL1
Am. J. Pathol., January 1, 2009; 174(1): 164 - 176.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
C. Riemer, J. Schultz, M. Burwinkel, A. Schwarz, S. W. F. Mok, S. Gultner, T. Bamme, S. Norley, F. van Landeghem, B. Lu, et al.
Accelerated Prion Replication in, but Prolonged Survival Times of, Prion-Infected CXCR3-/- Mice
J. Virol., December 15, 2008; 82(24): 12464 - 12471.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
M. Dubois-Dalcq, A. Williams, C. Stadelmann, B. Stankoff, B. Zalc, and C. Lubetzki
From fish to man: understanding endogenous remyelination in central nervous system demyelinating diseases
Brain, July 1, 2008; 131(7): 1686 - 1700.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
S. Sinha, S. Subramanian, T. M. Proctor, L. J. Kaler, M. Grafe, R. Dahan, J. Huan, A. A. Vandenbark, G. G. Burrows, and H. Offner
A Promising Therapeutic Approach for Multiple Sclerosis: Recombinant T-Cell Receptor Ligands Modulate Experimental Autoimmune Encephalomyelitis by Reducing Interleukin-17 Production and Inhibiting Migration of Encephalitogenic Cells into the CNS
J. Neurosci., November 14, 2007; 27(46): 12531 - 12539.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. M. Frohman, M. K. Racke, and C. S. Raine
Multiple sclerosis--the plaque and its pathogenesis.
N. Engl. J. Med., March 2, 2006; 354(9): 942 - 955.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.